Vivani Medical (VANI)
Develops subdermal implants designed for extended, steady drug delivery.
Something off on this page? Send us feedback.
Develops miniature, ultra-long-acting subdermal drug implant candidates using its NanoPortal platform. Biopharm programs center on GLP-1 candidates, while Cortigent holds legacy neurostimulation assets; no products are approved for commercial sale.
Develops miniature, ultra-long-acting subdermal drug implant candidates through its NanoPortal platform for chronic diseases. The implant design is intended to deliver medicines steadily over extended periods. Its Biopharm work centers on GLP-1 programs, including NPM-139, NPM-133 and NPM-115, plus the Okava-partnered OKV-119; none is approved for commercial sale.
Cortigent contains legacy Second Sight neurostimulation assets. The operating priority is clinical advancement of implant candidates, and the two-business structure remains shaped by a proposed, not completed, Cortigent separation. These programs are being advanced as clinical-stage biotechnology work rather than marketed therapies today.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 23, 2026 | Lake Street | Initiate | Rating: —Target: — | Target: $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.9M · Total debt $17.9M · Total assets $41.6M · Shareholders' equity $19.0M
- Revenue
- $0
- Operating income
- −$6.9M
- Net income
- −$6.4M
No dividends on record.
| Institutions | 5.78% | 5.22M shares | |
|---|---|---|---|
| 38 holders · as of Jun 30, 2026 | |||
| Insiders | 50.80% | 45.82M shares | |
| 3 holders · as of Jul 16, 2026 | |||
| Other | 43.42% | 39.16M shares | |
| remainder | |||
90.20M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gregg Williams1Insiderdirector, 10 percent owner | 50.55% | 43.22M | filed Jul 16, 2026 |
Vanguard Capital Management LLCInstitution | 1.96% | 1.77M | as of Jun 30, 2026 |
Tanager Wealth Management LLPInstitution | 0.67% | 607,276 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.65% | 587,745 | as of Jun 30, 2026 |
Tudor Investment Corp et alInstitution | 0.46% | 410,902 | as of Jun 30, 2026 |
- Gregg Williams's transaction reports restate only vehicles that traded; the 2026 ownership statement (43.22M) plus the 2.38M net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 15, 2026 | Gregg Williams | director, 10 percent owner: | +793,650 | $1.26 |
| Jun 15, 2026 | Gregg Williams | director, 10 percent owner: | +1,587,301 | $1.26 |
| May 15, 2026 | Gregg Williams | director, 10 percent owner: | +1,587,301 | $1.26 |
| Apr 15, 2026 | Gregg Williams | director, 10 percent owner: | +1,587,301 | $1.26 |
| Mar 15, 2026 | Gregg Williams | director, 10 percent owner: | +1,575,231 | $1.07 |
- Novo Nordisk (ADR)
Approved semaglutide products in obesity and diabetes
- Eli Lilly
Approved tirzepatide treatments in obesity and type 2 diabetes
- AstraZeneca (ADR)
Clinical GLP-1 program for obesity and type 2 diabetes
- Amgen
Late-stage long-acting GLP-1 therapy for obesity and diabetes
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vivani Medical | $1.24 | −2.36% | $109.5M | — | — | — | — |
| Novo Nordisk (ADR) | $38.30 | −2.79% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Eli Lilly | $1,147.76 | −1.91% | $1.10T | 39.3 | 28.1 | 13.8 | +47.7% |
| AstraZeneca (ADR) | $163.61 | −2.83% | $261.12B | 25.3 | 15.4 | 4.3 | +6.4% |
| Amgen | $405.53 | −1.15% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Median | 25.4 | 16.6 | 5.0 | +8.0% |